Arbutus Biopharma Corp SC TO-I, filed Aug 24, 2026
Arbutus Biopharma Corp (ABUS)
SECURITIES AND EXCHANGE COMMISSION
OF THE SECURITIES EXCHANGE ACT OF 1934
Chief Financial Officer
Arbutus Biopharma Corporation
701 Veterans Circle
Warminster, Pennsylvania 18974
(267) 469-0914
Stephen M. Nicolai
Hogan Lovells Cadwalader US LLP
1735 Market St.
Floor 23
Philadelphia, Pennsylvania 19103
(267) 675-4600
John O’Connell
Simpson Thacher & Bartlett LLP
425 Lexington Avenue
New York, NY 10017
(212) 455-2000
| | | | | Arbutus Biopharma Corporation | | |||
| | Date: August 24, 2026 | | | By: | | |
/s/ Lindsay Androski
|
|
| | | | | | | |
Name:
Lindsay Androski
|
|
| | | | | | | |
Title:
President and Chief Executive Officer
(Principal Executive Officer)
|
|
UP TO US$230 MILLION IN VALUE OF ITS COMMON SHARES AT A PURCHASE PRICE OF NOT LESS THAN US$5.00 AND NOT MORE THAN US$5.75 PER COMMON SHARE
| | | The Offer will expire at 5:00 p.m. (New York City time) on September 29, 2026, or at such later time and date to which the Offer may be extended by the Company, unless withdrawn. | | |
| |
The Depositary for the Offer is:
TSX Trust Company
|
| |
The Information Agent for the Offer is:
Georgeson, LLC
|
|
| |
Regular Mail:
TSX Trust Company 301-100 Adelaide Street West Toronto, Ontario M5H 4H1 |
| |
51 West 52nd Street, 6th Floor
New York, NY 10019 Shareholders, Banks and Brokers Toll Free: (877) 816-4522 |
|
| |
Registered Mail, Hand or Courier
TSX Trust Company 301-100 Adelaide Street West Toronto, Ontario M5H 4H1 Attention: Corporate Actions |
| |
The Dealer Manager for the Offer is:
J.P. Morgan Securities LLC
270 Park Avenue
New York, New York 10017 |
|
| | | | |
For shareholders in Canada only:
|
|
| |
For inquiries only:
Telephone (outside North America): (416) 682-3860 Toll Free (within North America): 1-800-387-0825 Email: tsxt-corpact@tmx.com |
| |
J.P. Morgan Securities Canada Inc.
Suite 4500, TD Bank Tower 66 Wellington Street West Toronto, Ontario Canada M5K 1E7 |
|
| | | |
Page
|
| |||
| | | | | vi | | | |
| | | | | vi | | | |
| | | | | vii | | | |
| | | | | ix | | | |
| | | | | ix | | | |
| | | | | x | | | |
| | | | | 1 | | | |
| | | | | 6 | | | |
| | | | | 6 | | | |
| | | | | 6 | | | |
| | | | | 8 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 16 | | | |
| | | | | 17 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 22 | | | |
| | | | | 24 | | | |
| | | | | 24 | | | |
| | | | | 24 | | | |
| | | | | 24 | | | |
| | | | | 30 | | | |
| | | | | 30 | | | |
| | | | | 31 | | | |
| | | | | 31 | | | |
| | | | | 31 | | | |
| | | | | 31 | | | |
| | | | | 32 | | | |
| | | | | 39 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 41 | | | |
| | | | | 49 | | | |
| | | | | 49 | | | |
| | | | | 49 | | | |
| | | | | 50 | | | |
| | | | | 50 | | | |
| | | | | 51 | | | |
| | | | | 52 | | | |
| | | | | 53 | | | |
| |
Purpose of the Offer
|
| |
The Board of Directors believes that the purchase of Shares by the Company is in the best interests of the Company and its Shareholders. On July 8, 2026, the Company received $178 million as its share of the noncontingent payment under the settlement agreement (the “Settlement Agreement”) entered into with Moderna to resolve all global patent infringement litigation and patent revocation proceedings related to Moderna’s infringement of patents protecting Arbutus’ industry-leading LNP technology in Moderna’s COVID-19 vaccines and other products. In connection with the receipt of these funds, the Board of Directors believes that the Offer represents an efficient mechanism to provide Shareholders with an opportunity to sell a significant portion of their Shares at a premium over current market prices and thereby to receive a return of some or all of their investment in the Company, while also permitting them the opportunity to retain a continuing interest in the Company. The Offer provides a mechanism for completing a sizeable repurchase of Shares more rapidly than would be possible through open market repurchases in compliance with applicable United States and Canadian securities laws.
The Offer also provides Shareholders with an efficient way to sell their Shares without incurring brokerage fees or commissions associated with open market sales; however, Shareholders who hold Shares through nominees are urged to consult their nominees to determine whether transaction costs may apply.
Shareholders who are holders of vested options may exercise their vested options and tender any of the Shares issued upon exercise. Shareholders must exercise their options on or prior to 5:00PM ET on September 22, 2026 to receive their Shares in order to tender. An exercise of an option cannot be revoked even if Shares received upon the exercise thereof and tendered in the Offer are not purchased in the Offer for any reason. Shareholders who are holders of RSUs may only tender Shares that such Shareholders have acquired through vesting of such RSUs. Shareholders who are participants in the Company’s ESPP may tender Shares that such Shareholders have purchased through the ESPP, including Shares purchased through the ESPP up to and including the purchase period ending on August 31, 2026. Shareholders may not tender Shares that such Shareholders are eligible to purchase in the purchase period that will end on February 28, 2027 (even if such Shareholders have made purchase contributions via payroll deductions prior to the end of the Offer).
The Offer will allow the Company to return up to $230 million of capital to Shareholders who elect to tender their Shares while at the same time increasing the Share ownership of Shareholders who elect not to tender.
See Section 5 of the Offer to Purchase, “Procedure for Depositing Shares” and Section 3 of the Circular, “Purpose and Effect of the Offer”.
|
|
| |
Expiration Date
|
| | The Offer expires at 5:00 p.m. (New York City time) on September 29, 2026 or at such later time and date to which the Offer may be extended by the Company, unless withdrawn. See Section 1 of the Offer to Purchase, “The Offer”. | |
| |
Payment Date
|
| | The Company will comply with both U.S. and Canadian regulations governing the timing for acceptance of and payment for Shares, except to the extent that it has obtained exemptive relief from those requirements from the applicable regulatory authorities. Under U.S. regulations, Arbutus is required to promptly accept for | |
| | | | |
payment and promptly thereafter pay for all Shares validly tendered and not properly withdrawn prior to the Expiration Date pursuant to the Offer. Under Canadian regulations, Arbutus must take up the Shares to be purchased pursuant to the Offer as soon as reasonably practicable after the Expiration Date and in any event not later than 10 days after the Expiration Date, provided that the conditions of the Offer (as the same may be varied) have been satisfied or waived. Any Shares taken up will be paid for in accordance with applicable U.S. and Canadian securities laws. See Section 9 of the Offer to Purchase, “Taking Up and Payment for Deposited Shares”.
The Company expects to accept and pay for Shares validly tendered and not validly withdrawn prior to the Expiration Date on or about October 2, 2026, the third Business Day following the Expiration Date (assuming the Expiration Date is not extended beyond September 29, 2026), or promptly thereafter.
|
|
| |
Currency of Payment
|
| | The Purchase Price will be denominated in United States dollars and payments of amounts owing to Shareholders whose Shares are taken up will be made in United States dollars. However, Shareholders may elect to receive the Purchase Price in an amount of Canadian dollars determined using the applicable exchange rate as described in the Offer. In such case, the risk of any fluctuation in exchange rates, including risks related to the particular date and time at which funds are converted, will be borne solely by the Shareholder. See Section 2 of the Offer to Purchase, “Purchase Price”. | |
| |
Methods of Tender
|
| |
Shareholders wishing to tender to the Offer may do so pursuant to:
•
Auction Tenders in which the tendering Shareholders specify the number of Shares being tendered and specify an Auction Price of not less than $5.00 and not more than $5.75 per Share in increments of $0.05 per Share;
•
Purchase Price Tenders in which the tendering Shareholders do not specify a price per Share, but rather agree to have a specified number of Shares purchased at the Purchase Price to be determined pursuant to the Offer; or
•
Proportionate Tenders in which the tendering Shareholders agree to sell to the Company, at the Purchase Price to be determined pursuant to the Offer, a number of Shares that will result in them maintaining their respective proportionate Share ownership in the Company following completion of the Offer. See Section 1 of the Offer to Purchase, “The Offer”.
|
|
| |
Purchase Price
|
| |
The Purchase Price will be determined in the manner described in the Offer, taking into account the Auction Prices and the number of Shares deposited pursuant to Auction Tenders and Purchase Price Tenders, but will be not less than $5.00 and not more than $5.75 per Share. The Purchase Price will be the lowest price that enables the Company to purchase that number of Shares pursuant to valid Auction Tenders and Purchase Price Tenders having an aggregate purchase price not exceeding the Auction Tender Limit Amount.
All Shares purchased by the Company pursuant to the Offer (including Shares tendered at Auction Prices below the Purchase Price) will be purchased at the same Purchase Price.
A Shareholder making an Auction Tender may deposit different Shares at different prices, but a Shareholder cannot deposit the same Shares pursuant to more than one method of tender or pursuant to an Auction Tender at more than one price. Shareholders may deposit different Shares pursuant to Auction Tenders and Purchase Price Tenders but cannot make an Auction Tender or Purchase Price Tender as well as a Proportionate Tender.
|
|
| | | | | The Company will return all Shares not purchased under the Offer, including Shares not purchased as a result of proration or invalid tender or Shares deposited pursuant to Auction Tenders at prices in excess of the Purchase Price, promptly after the Expiration Date. See Section 2 of the Offer to Purchase, “Purchase Price”. | |
| |
Number of Shares to be Purchased
|
| | Arbutus will purchase Shares under the Offer to a maximum aggregate amount of $230 million. Since the Purchase Price will only be determined after the Expiration Date, the number of Shares that will be purchased will not be known until after the Expiration Date. If the Auction Tender Purchase Amount is equal to or greater than the Auction Tender Limit Amount, the Company will repurchase a total number of Shares having an aggregate value equal to $230 million. If the Auction Tender Purchase Amount is less than the Auction Tender Limit Amount, the Company will repurchase a total number of Shares having an aggregate purchase price equal to the product of (i) $230 million, and (ii) a fraction, the numerator of which is the Auction Tender Purchase Amount, and the denominator of which is the Auction Tender Limit Amount. See Section 3 of the Offer to Purchase, “Number of Shares, Proration and Proportionate Tenders”. | |
| |
Proration
|
| |
If the aggregate purchase price for Shares validly tendered and not validly withdrawn pursuant to Auction Tenders at Auction Prices at or below the Purchase Price and Purchase Price Tenders is less than or equal to the Auction Tender Limit Amount, the Company will purchase at the Purchase Price all Shares so tendered pursuant to Auction Tenders at or below the Purchase Price and Purchase Price Tenders.
If the Auction Tender Purchase Amount is greater than the Auction Tender Limit Amount, the Company will purchase a portion of the Shares so tendered pursuant to Auction Tenders at or below the Purchase Price and Purchase Price Tenders, as follows: (i) first, the Company will purchase all Shares tendered at or below the Purchase Price by Odd Lot Holders who have tendered all of their Shares at or below the Purchase Price; and (ii) second, the Company will purchase at the Purchase Price on a pro rata basis that portion of the Shares tendered pursuant to Auction Tenders at or below the Purchase Price and Purchase Price Tenders having an aggregate purchase price, based on the Purchase Price, equal to (A) the Auction Tender Limit Amount, less (B) the aggregate amount paid by the Company for Shares tendered by Odd Lot Holders. The Company will purchase at the Purchase Price, payable in cash, less any applicable withholding taxes and without interest, a number of Shares from Shareholders making valid Proportionate Tenders that results in such tendering Shareholders maintaining their respective proportionate Share ownership in the Company following completion of the Offer (subject to nominal differences due to the quantity of Shares purchased from such Shareholders being rounded down to the nearest whole number of Shares to avoid the purchase of fractional Shares). See Section 3 of the Offer to Purchase, “Number of Shares, Proration and Proportionate Tenders”.
|
|
| |
Delivery Procedure
|
| |
Each Shareholder wishing to deposit Shares pursuant to the Offer must:
•
provide a properly completed and duly executed Letter of Transmittal, in accordance with the instructions in such Letter of Transmittal, which must be accompanied by certificates for any Deposited Shares that are represented by physical share certificates, together with all other documents required by the Letter of Transmittal and must be delivered to, and received by, the Depositary at one of the addresses listed in the Letter of Transmittal by the Expiration Date;
•
follow the guaranteed delivery procedure described in Section 5 of the Offer to Purchase, “Procedure for Depositing Shares”; or
•
transfer Shares pursuant to a book-entry transfer, provided that a Book-Entry Confirmation through the CDSX system (in the case of Shares held in CDS) or an Agent’s Message (in the case of Shares held in DTC) is received by the Depositary
|
|
| | | | |
at its office in Toronto, Ontario prior to the Expiration Date (as such terms are defined herein).
A Shareholder who wishes to deposit Shares under the Offer and who holds such Shares through an investment dealer, stock broker, bank, trust company or other nominee should immediately contact such nominee in order to take the necessary steps to be able to deposit such Shares under the Offer. See Section 5 of the Offer to Purchase, “Procedure for Depositing Shares”.
|
|
| |
Brokerage Commissions
|
| | Shareholders depositing Shares will not be obligated to pay brokerage fees or commissions to the Company or to the Depositary. However, Shareholders are cautioned to consult with their own brokers or other intermediaries to determine whether any fees or commissions are payable to their own brokers or other intermediaries in connection with a deposit of Shares pursuant to the Offer. See Section 9 of the Offer to Purchase, “Taking Up and Payment for Deposited Shares”. | |
| |
Conditions to the Offer
|
| | The obligation of the Company to take up and pay for any Shares deposited under the Offer is subject to the conditions described in Section 7 of the Offer to Purchase, “Certain Conditions of the Offer”. | |
| |
Withdrawal Rights
|
| | Shares deposited pursuant to the Offer may be withdrawn by the Shareholder (a) at any time if the Shares have not been taken up (i.e., accepted for purchase) by the Company before actual receipt by the Depositary of a notice of withdrawal in respect of such Shares, (b) at any time before the expiration of ten (10) days from the date that a notice of change or variation (unless (i) the variation consists solely of an increase in the consideration offered for those Shares pursuant to the Offer where the time for deposit is not extended for greater than ten days, or (ii) the variation consists solely of the waiver of a condition of the Offer) has been given in accordance with Section 8 of the Offer to Purchase, “Extension and Variation of the Offer”, or (c) at any time if the Shares have been taken up but not paid for by the Company within three Business Days of being taken up. In addition, pursuant to Rule 13e-4(f) under the Exchange Act, Shares may also be withdrawn after October 21, 2026, which is the 40th Business Day (for purposes of United States federal holidays) after the date of the commencement of the Offer, unless such Shares have already been accepted for payment by the Company pursuant to the Offer and not validly withdrawn. | |
| |
Position of the Company and its Directors
|
| | Neither the Company nor its Board of Directors makes any recommendation to any Shareholder as to whether to deposit or refrain from depositing Shares. Shareholders are urged to evaluate carefully all information in the Offer, consult their own investment and tax advisors and make their own decisions whether to deposit Shares under the Offer, how many Shares to deposit and whether to specify a price and, if so, at what price to deposit such Shares. See Section 1 of the Offer to Purchase, “The Offer”. | |
| |
Interest of Affiliate
|
| |
Roivant is the beneficial owner of 38,847,462 Shares, which represents approximately 19.6% of all issued and outstanding Shares as of August 19, 2026. Roivant has advised the Company that it intends to make a Proportionate Tender. The Company’s Chief Executive Officer and Chairperson of the Board of Directors, Lindsay Androski, is also employed by RSI, a wholly-owned subsidiary of Roivant, where she serves as President of Roivant Social Ventures, and as Special Counsel at Genevant, also a subsidiary of Roivant. Two of the Company’s other directors are employed by RSI: Matthew Gline, RSI’s Chief Executive Officer, and Joseph Bishop, RSI’s Senior Vice President, Finance.
See Section 11 of the Circular, “Arrangements Concerning Shares.”
|
|
| |
Directors & Officers
|
| | We have been advised that certain of our directors and officers of the Company named under Section 10 of the Circular, “Interest of Directors and Officers — Ownership of Arbutus’ Securities”, intend to participate in the Offer and tender up to an aggregate of 682,630 Shares through Purchase Price Tenders. See Section 10 | |
| | | | | “Interest of Directors and Officers — Ownership of Arbutus’ Securities” and Section 11 “Arrangements Concerning Shares” of the Circular. | |
| |
Tax Considerations
|
| | Shareholders should carefully consider the income tax consequences of having Shares being purchased under the Offer. See Section 14 of the Circular, “Income Tax Considerations”. | |
| |
Trading Information
|
| | On August 21, 2026, the last full trading day prior to the commencement of the Offer, the closing price of the Shares on Nasdaq was $5.21 per Share, which is above the $5.00 per Share lower end of the price range for the Offer. Accordingly, an election to accept the Purchase Price determined in the Offer may lower the Purchase Price to a price below such closing price and could be below the reported closing price on the Expiration Date. During the 12-month period ended August 21, 2026, the closing prices of the Shares on Nasdaq has ranged from a low of $3.50 to a high of $5.22. See Section 5 of the Circular, “Price Range of Shares”. | |
| |
Further Information
|
| | For further information regarding the Offer, Shareholders may contact the Depositary, the Information Agent or the Dealer Manager or consult their own brokers. The address and telephone numbers and email of the Depositary, the Information Agent and Dealer Manager are set forth on page iv and the back cover of the Offer. See Section 18 of the Circular, “Depositary and Information Agent.” | |
Chief Executive Officer
|
Month
|
| |
High
|
| |
Low
|
| |
Total Volume
|
| |||||||||
| | | |
(US$)
|
| |
(US$)
|
| |
(#)
|
| |||||||||
| 2026 | | | | | | | | | | | | | | | | | | | |
|
August (1 – 19)
|
| | | $ | 5.18 | | | | | $ | 4.31 | | | | | | 18,654,568 | | |
|
July
|
| | | $ | 5.38 | | | | | $ | 4.25 | | | | | | 44,949,900 | | |
|
June
|
| | | $ | 4.87 | | | | | $ | 4.06 | | | | | | 49,308,300 | | |
|
May
|
| | | $ | 4.79 | | | | | $ | 4.06 | | | | | | 27,488,000 | | |
|
April
|
| | | $ | 4.75 | | | | | $ | 4.01 | | | | | | 43,297,200 | | |
|
March
|
| | | $ | 4.85 | | | | | $ | 4.14 | | | | | | 68,090,600 | | |
|
February
|
| | | $ | 4.80 | | | | | $ | 3.50 | | | | | | 39,112,600 | | |
|
January
|
| | | $ | 5.00 | | | | | $ | 3.68 | | | | | | 29,310,800 | | |
| 2025 | | | | | | | | | | | | | | | | | | | |
|
December
|
| | | $ | 5.07 | | | | | $ | 4.09 | | | | | | 29,013,400 | | |
|
November
|
| | | $ | 4.87 | | | | | $ | 4.08 | | | | | | 20,217,900 | | |
|
October
|
| | | $ | 4.95 | | | | | $ | 4.10 | | | | | | 21,971,100 | | |
|
September
|
| | | $ | 5.10 | | | | | $ | 3.66 | | | | | | 33,456,000 | | |
|
August
|
| | | $ | 3.73 | | | | | $ | 3.26 | | | | | | 17,204,200 | | |
| | | |
High
|
| |
Low
|
| ||||||
| 2024: | | | | | | | | | | | | | |
|
First Quarter
|
| | | $ | 2.92 | | | | | $ | 2.26 | | |
|
Second Quarter
|
| | | $ | 3.63 | | | | | $ | 2.52 | | |
|
Third Quarter
|
| | | $ | 4.56 | | | | | $ | 3.12 | | |
|
Fourth Quarter
|
| | | $ | 4.20 | | | | | $ | 3.18 | | |
| 2025: | | | | | | | | | | | | | |
|
First Quarter
|
| | | $ | 3.59 | | | | | $ | 3.06 | | |
|
Second Quarter
|
| | | $ | 3.61 | | | | | $ | 2.88 | | |
|
Third Quarter
|
| | | $ | 4.90 | | | | | $ | 3.13 | | |
|
Fourth Quarter
|
| | | $ | 4.95 | | | | | $ | 4.11 | | |
| 2026: | | | | | | | | | | | | | |
|
First Quarter
|
| | | $ | 4.88 | | | | | $ | 3.67 | | |
|
Second Quarter
|
| | | $ | 4.80 | | | | | $ | 4.12 | | |
|
Third Quarter (through August 19, 2026)
|
| | | $ | 5.22 | | | | | $ | 4.29 | | |
|
Year of Distribution
|
| |
Number of Shares
Issued (#) |
| |
Average Price per
Issued Share ($) |
| |
Aggregate
Proceeds ($) |
| |||||||||
|
2026 (through August 19, 2026)
|
| | | | — | | | | | | — | | | | | | — | | |
|
2025
|
| | | | — | | | | | | — | | | | | | — | | |
|
2024
|
| | | | 16,499,999 | | | | | | 2.76 | | | | | | 45,488,253 | | |
|
2023
|
| | | | 12,020,257 | | | | | | 2.57 | | | | | | 30,869,468 | | |
|
2022
|
| | | | 12,225,378 | | | | | | 2.96 | | | | | | 36,166,913 | | |
|
2021
|
| | | | 35,571,036 | | | | | | 4.41 | | | | | | 139,156,606 | | |
|
Year of Distribution
|
| |
Shares Issued on
Exercise/Settlement (#) |
| |
Average Price
per Issued Share ($) |
| |
Aggregate
Value ($) |
| |||||||||
|
2026 (through August 19, 2026)
|
| | | | 5,574,518 | | | | | | 3.12 | | | | | | 17,385,814 | | |
|
2025
|
| | | | 2,567,733 | | | | | | 2.97 | | | | | | 7,619,763 | | |
|
2024
|
| | | | 3,596,079 | | | | | | 2.47 | | | | | | 8,864,623 | | |
|
2023
|
| | | | 391,794 | | | | | | 2.03 | | | | | | 794,433 | | |
|
2022
|
| | | | 242,248 | | | | | | 2.13 | | | | | | 516,803 | | |
|
2021
|
| | | | 904,056 | | | | | | 2.84 | | | | | | 2,570,844 | | |
|
Name
|
| |
Relationship with Company
|
| |
Number of
Shares Beneficially Owned(1) |
| |
% of
Outstanding Shares(11) |
| |
Number
of Options |
| |
% of
Outstanding Options |
| |
Number
of RSUs |
| |
% of
Outstanding RSUs |
| ||||||||||||||||||
| Executive Officers and Directors | | |||||||||||||||||||||||||||||||||||||||
|
Lindsay Androski
|
| |
President and Chief
Executive Officer and Chairperson |
| | | | 134,825(2) | | | | | | * | | | | | | 382,122 | | | | | | 5.5% | | | | | | 28,000 | | | | | | 2.4% | | |
|
Tuan Nguyen
|
| |
Chief Financial
Officer |
| | | | 312,650(3) | | | | | | * | | | | | | 938,400 | | | | | | 13.6% | | | | | | 73,500 | | | | | | 6.2% | | |
|
Robert Alan Beardsley
|
| |
Director
|
| | | | 131,333(4) | | | | | | * | | | | | | 236,400 | | | | | | 3.4% | | | | | | — | | | | | | — | | |
|
Joseph Bishop
|
| |
Director
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
|
Matthew Gline
|
| |
Director
|
| | | | 38,847,462(5) | | | | | | 19.6% | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
|
Roger Sawhney
|
| |
Director
|
| | | | 131,333 (6) | | | | | | * | | | | | | 236,400 | | | | | | 3.4% | | | | | | — | | | | | | — | | |
|
All current directors and executive officers as a group (6 persons)(11)
|
| | | | 39,557,603 | | | | | | 19.9% | | | | | | 1,793,322 | | | | | | 26.0% | | | | | | 101,500 | | | | | | 8.6% | | | |||
| Greater than 5% Shareholders | | |||||||||||||||||||||||||||||||||||||||
|
Roivant Sciences Ltd.(5)
|
| |
Shareholder
|
| | | | 38,847,462(5) | | | | | | 19.6% | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
|
Entities affiliated with Morgan
Stanley |
| |
Shareholder
|
| | | | 17,387,398(7) | | | | | | 8.8% | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
|
Entities affiliated with Whitefort Capital Management, LP
|
| |
Shareholder
|
| | | | 15,794,261(8) | | | | | | 8.0% | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
|
Entities affiliated with Two Seas Capital LP
|
| |
Shareholder
|
| | | | 18,557,543(9) | | | | | | 9.4% | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
|
Entities affiliated with Blackrock,
Inc. |
| |
Shareholder
|
| | | | 10,390,300(10) | | | | | | 5.2% | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
|
Name
|
| |
Date of Transaction
|
| |
Nature of Transaction
|
| |
Number of
Shares |
| |
Exercise
Price Per Option Award |
| ||||||
|
Robert A. Beardsley(1)
|
| |
June 8, 2026
|
| |
Grant of stock options (right to buy)
pursuant to the Company’s 2026 Omnibus Incentive Plan |
| | | | 78,800 | | | | | $ | 4.24 | | |
|
Roger Sawhney(2)
|
| |
June 8, 2026
|
| |
Grant of stock options (right to buy)
pursuant to the Company’s 2026 Omnibus Incentive Plan |
| | | | 78,800 | | | | | $ | 4.24 | | |
| |
/s/ Lindsay Androski
|
| |
/s/ Tuan Nguyen
|
|
| |
Lindsay Androski
|
| |
Tuan Nguyen
|
|
| |
Chief Executive Officer and
Chairperson of the Board of Directors |
| |
Chief Financial Officer
|
|
| |
/s/ Robert Alan Beardsley
|
| |
/s/ Roger Sawhney
|
|
| |
Robert Alan Beardsley
|
| |
Roger Sawhney
|
|
| |
Director
|
| |
Director
|
|
301-100 Adelaide Street West
Toronto, Ontario M5H 4H1
Attention: Corporate Actions
301-100 Adelaide Street West
Toronto, Ontario M5H 4H1
Attention: Corporate Actions
Telephone (outside North America): (416) 682-3860
Toll Free (within North America): 1-800-387-0825
Email: shareholderinquiries@tmx.com
| | | Any questions or requests for assistance regarding the Offer may be directed to the Depositary at the addresses and telephone numbers and email specified above. Shareholders also may contact their investment dealer, stock broker, bank, trust company or other nominee for assistance concerning the Offer. Additional copies of the Offer to Purchase, the Circular, the Letter of Transmittal and the Notice of Guaranteed Delivery may be obtained from the Depositary. Manually executed photocopies of the Letter of Transmittal will be accepted. | | |
| | |
51 West 52nd Street, 6th Floor
New York, NY 10019
Shareholders, Banks and Brokers
Toll Free: (877) 816-4522
|
| |
J.P. Morgan Securities LLC
270 Park Avenue
New York, New York 10017
Suite 4500, TD Bank Tower
66 Wellington Street West
Toronto, Ontario
Canada M5K 1E7
UP TO US$230 MILLION IN VALUE OF ITS COMMON SHARES AT A PURCHASE PRICE OF NOT LESS THAN US$5.00 AND NOT MORE THAN US$5.75 PER COMMON SHARE
Common Shares
of
Arbutus Biopharma Corporation
Pursuant to the Offer (as defined herein)
Dated August 24, 2026
| | |
THE OFFER WILL EXPIRE AT 5:00 PM (NEW YORK CITY TIME) ON SEPTEMBER 29, 2026, OR AT SUCH LATER TIME AND DATE TO WHICH THE OFFER MAY BE EXTENDED BY THE COMPANY, UNLESS WITHDRAWN
(THE “EXPIRATION DATE”) |
| |
Toronto, Ontario, M5H 4H1
Toll Free: 1-800-387-0825
Email: tsxt-corpact@tmx.com
| | |
This Letter of Transmittal is to be used only if certificates for Shares (as defined below) are to be forwarded with it or if the Shares are held through the Direct Registration System (DRS), pursuant to Section 5 of the Offer, “Procedure for Depositing Shares.”
|
| |
| | |
NAME(S) OF REGISTERED OWNER(S)
(Please Fill in Exactly as Name(s) Appear(s) on Share Certificate(s) OR DRS Account Statement) |
| |
| | | | |
| | |
DESCRIPTION OF SHARES DEPOSITED
(Attach signed list if necessary) |
| | ||||||||
| | |
Share Certificate Number(s)
or DRS Account Number(s) |
| | |
Number of shares Represented by Certificate(s) or held through DRS
|
| | |
Number of shares Deposited*
|
| |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | |
TOTAL:
|
| | | | | |
| | |
BOX A
TYPE OF TENDER
CHECK ONLY ONE BOX, IF MORE THAN ONE BOX IS CHECKED, OR IF NO BOX IS CHECKED, THE TENDER WILL BE DEEMED TO BE A PURCHASE PRICE TENDER.
SHARES ARE BEING TENDERED HEREBY PURSUANT TO:
|
| | ||||||
| | | ☐ An Auction Tender | | | ☐ A Purchase Price Tender | | | ☐ A Proportionate Tender | | |
| | |
(Complete Box G)
|
| | | | |
(Complete Box B)
|
| |
| | |
BOX B PROPORTIONATE TENDER
|
| | ||||
| | |
In addition to checking “Proportionate Tender” in Box A above, this Box B MUST be completed if Shares are being tendered pursuant to a Proportionate Tender.
A Shareholder who makes a Proportionate Tender will be deemed to have agreed to sell to the Company at the Purchase Price a number of Shares that will result in the Shareholder maintaining its proportionate equity ownership in the Company following completion of the Offer. Registered Shareholders may make a Proportionate Tender and non-registered Shareholders may instruct their nominees to make a Proportionate Tender. All Shareholders who make a Proportionate Tender must indicate the total number of Shares they own below. A registered Shareholder who makes a Proportionate Tender must deposit either all of its Shares or a sufficient number of Shares to satisfy the Shareholder’s Proportionate Tender. This number of Shares can be calculated by multiplying the total number of Shares owned by the Shareholder by 0.2322 (rounded down to the nearest whole number of Shares). A non-registered Shareholder who wishes its nominee to make a Proportionate Tender must deposit all of its Shares.
If a non-registered Shareholder wishes to become a registered Shareholder in order to make a Proportionate Tender by depositing only a sufficient number of Shares, the Shareholder should immediately contact its investment dealer, stock broker, bank, trust company or other nominee in order to take the necessary steps to have its Shares registered in the Shareholder’s name prior to tendering Shares pursuant to the Offer. A Shareholder who makes an invalid Proportionate Tender, including by tendering an insufficient number of Shares to satisfy the Proportionate Tender, will be deemed to have made a Purchase Price Tender with respect to all such Shares.
|
| | ||||
| | | | | | | | | |
| | | Total number of Shares owned by the Shareholder: | | | | | | |
| | |
BOX C
Payment Instructions |
| |
| | |
ISSUE CONSIDERATION CHECK IN THE NAME OF:
|
| |
| | | By default, your consideration payment will be issued to your name as it appears on the company register. If you wish for your payment to be issued in another name, see Instruction 6 below. | | |
| | |
(NAME)
|
| |
| | |
(STREET NUMBER & NAME)
|
| |
| | |
(CITY AND PROVINCE/STATE)
|
| |
| | |
(COUNTRY AND POSTAL/ZIP CODE)
|
| |
| | |
(TELEPHONE NUMBER (BUSINESS HOURS))
|
| |
| | |
(SOCIAL INSURANCE/SECURITY NUMBER)
|
| |
| | |
(IDENTIFICATION NUMBER)
U.S. residents/citizens must provide their Taxpayer Identification Number |
| |
| | |
If the funds payable in cash exceed US$25,000,000, they must be wired to you and the Depositary will contact you.
|
| |
| | |
☐ MAIL CHECK TO THE ADDRESS ON RECORD (DEFAULT)
☐ MAIL CHECK TO A DIFFERENT ADDRESS (MUST COMPLETE BOX D)
☐ PAYMENT BY WIRE (MUST COMPLETE BOX L)
☐ HOLD CHECK FOR PICK-UP AT TSX TRUST COMPANY OFFICE AT 100 ADELAIDE ST, SUITE 301, TORONTO ON
|
| |
| | |
BOX D
Delivery Instructions |
| |
| | |
SEND CHECK TO:
|
| |
| | | (To be completed ONLY if the Consideration check to which the undersigned is entitled is to be sent to someone other than the person shown in Box C or to an address other than the address shown in Box C.) | | |
| | |
(NAME)
|
| |
| | |
(STREET NUMBER & NAME)
|
| |
| | |
(CITY AND PROVINCE/STATE)
|
| |
| | |
(COUNTRY AND POSTAL/ZIP CODE)
|
| |
| | |
(TELEPHONE NUMBER (BUSINESS HOURS))
|
| |
| | |
(SOCIAL INSURANCE/SECURITY NUMBER)
|
| |
| | |
BOX E
ODD LOTS* |
| |
| | |
To be completed ONLY if Shares are being tendered by or on behalf of persons owning fewer than 100 Shares as of the close of business on the Expiration Date.
The undersigned either (check one):
☐
is the owner of fewer than 100 Shares as of the close of business on the Expiration Date, all of which are tendered; or
☐
is a broker, dealer, commercial bank, trust company or other nominee that (i) is tendering, for the beneficial owners thereof, Shares with respect to which it is the record owner, and (ii) believes, based upon representations made to it by each such beneficial owner, that such beneficial owner owns an aggregate of fewer than 100 Shares as of the close of business on the Expiration Date and is tendering all such Shares.
Odd Lot Holders may not tender their Shares pursuant to a Proportionate Tender.
|
| |
| | |
BOX F
GUARANTEED DELIVERY |
| |
| | |
CHECK HERE ☐ IF SHARES ARE BEING TENDERED PURSUANT TO A NOTICE OF GUARANTEED DELIVERY PREVIOUSLY SENT TO THE TORONTO OFFICE OF THE DEPOSITARY AND COMPLETE
THE FOLLOWING (please print or type) |
| |
| | |
Name of Registered Holder
|
| |
| | |
Date of Guaranteed Delivery
|
| |
| | |
Name of Institution which Guaranteed Delivery
|
| |
| | |
|
| |
| | |
|
| |
| | |
|
| |
| | |
|
| |
| | |
BOX G
AUCTION TENDERS |
| | |||||||||||||||||||||
| | |
In addition to checking “Auction Tender” in Box A above, this Box G MUST be completed if Shares are being tendered pursuant to an Auction Tender.
Check only ONE box to indicate the Auction Tender price. If more than one box is checked, or if no box is checked, all Shares identified above will be deemed to have been tendered pursuant to the Purchase Price Tender. Shareholders (other than Odd Lot Holders) may make multiple Auction Tenders but not in respect of the same Shares. If a Shareholder wishes to tender different Shares at different prices, a separate tender instruction by way of Letter of Transmittal must be submitted for EACH such tender.
Price (in US$) per Share.
|
| | |||||||||||||||||||||
| | | ☐ $5.00 | | | ☐ $5.05 | | | ☐ $5.10 | | | ☐ $5.15 | | | ☐ $5.20 | | | ☐ $5.25 | | | ☐ $5.30 | | | ☐ $5.35 | | |
| | | ☐ $5.40 | | | ☐ $5.45 | | | ☐ $5.50 | | | ☐ $5.55 | | | ☐ $5.60 | | | ☐ $5.65 | | | ☐ $5.70 | | | ☐ $5.75 | | |
| | |
BOX H
CURRENCY ELECTION |
| | |||||||||||||||||||||
| | |
All cash payments will be made in U.S. dollars, unless Shareholders elect to use the Depositary’s currency exchange services to convert their payment into, and have such payment made, in Canadian dollars by checking the box below. If you do not check the box below, your payment will be issued in U.S. dollars.
☐ Check here if you wish to have your cash entitlement paid in Canadian dollars (C$)
|
| | |||||||||||||||||||||
| | |
Notice: By checking the box above, you acknowledge and agree that (a) the exchange rate for one U.S. dollar expressed in Canadian dollars will be the rate available from TSX Trust Company, in its capacity as foreign exchange service provider, on the date on which the funds are converted, which rate will be based on the prevailing market rate on such date, and (b) the risk of any fluctuations in such rate, including risks relating to the particular date and time at which funds are converted, will be solely borne by the Shareholder. TSX Trust Company will act as principal in such currency conversion transactions. If you wish to receive your payment in Canadian dollars, this validly-completed and duly-signed Letter of Transmittal must be delivered to the Depositary together with any certificate(s) representing Shares evidenced by physical certificates.
|
| | |||||||||||||||||||||
| | |
BOX I
JURISDICTION OF RESIDENCE (See Instruction 12) |
| | |||||||||||||||||||||
| | |
The person signing Box J represents that the Shareholder:
☐ is a non-resident of Canada for the purposes of the Tax Act; or
☐ is not a non-resident of Canada for purposes of the Tax Act.
Note:
A non-resident of Canada is a person that is not resident, or deemed not to be resident, in Canada for purposes of the Tax Act or a partnership that is not a “Canadian partnership” as defined in the Tax Act. If you are uncertain as to your residency or the residency of the beneficial holder(s) of the Shares, you should consult your tax advisor.
The remainder of this Box is for non-residents of Canada only:
The Shareholder ☐ is ☐ is not a resident of a country with which Canada has entered into an income tax treaty under which the Shareholder is entitled to the full benefits provided by such treaty.
If the non-resident Shareholder is entitled to full benefits under such treaty complete the following:
|
| | |||||||||||||||||||||
| | |
Country of Residence
|
| | |||||||||||||||||||||
| | |
BOX J
SHAREHOLDER(S) SIGN HERE (See Instructions 1 and 6)
Must be signed by registered owner(s) exactly as name(s) appear(s) on certificate(s) or Direct Registration System (DRS) account statement(s) or by person(s) authorized to become registered owner(s) by certificate(s) or other instruments of transfer and other documents transmitted with this Letter of Transmittal. If signature is by attorney-in-fact, executor, administrator, trustee, guardian, officer of a corporation or another acting in a fiduciary or representative capacity, please set forth the full title. See Instruction 6.
|
| |
| | |
Authorized Signature:
Signature(s) of Shareholder or authorized representative
Name(s):
(Please Print)
|
| |
| | |
Capacity(s):
|
| |
| | |
Address:
(Include Postal Code or Zip Code)
Area Code and Telephone Number:
TIN; SSN; SIN:
Shareholders must provide their Social Insurance No.; U.S. Shareholders must provide their Taxpayer Identification No. or Social Security No. and complete Form W-9. Non-resident Shareholder must complete Form NR-301 (or, in the case of a partnership or hybrid entity, Form NR-302 or NR-303, as applicable) where such Forms have not previously been provided or where details are no longer accurate.
Dated , 2026
|
| |
| | |
BOX K
GUARANTEE OF SIGNATURE(S) (See Instructions 1 and 6)
Authorized Signature:
|
| |
| | |
Name(s):
(Please Print)
|
| |
| | |
Title:
|
| |
| | |
Name of Firm:
|
| |
| | |
Address:
|
| |
| | |
(Include Postal Code or Zip Code)
|
| |
| | |
Area Code and Telephone Number:
|
| |
| | | Dated , 2026 | | |
| |
BOX L
WIRE PAYMENT |
| |||||||||
| | *PLEASE NOTE THAT THERE IS A $100 BANKING FEE DEDUCTED ON WIRE PAYMENTS. ALTERNATIVELY, CHECK PAYMENTS ARE ISSUED AT NO ADDITIONAL COST. | | |||||||||
| | *IF WIRE DETAILS ARE INCORRECT OR INCOMPLETE, TSX TRUST COMPANY WILL ATTEMPT TO CONTACT YOU AND CORRECT THE ISSUE. HOWEVER, IF WE CANNOT CORRECT THE ISSUE PROMPTLY, A CHECK WILL BE AUTOMATICALLY ISSUED AND MAILED TO THE ADDRESS ON RECORD. NO FEES WILL BE CHARGED. | | |||||||||
| | Please provide email address and phone number in the event that we need to contact you for corrective measures: | | |||||||||
| |
EMAIL
ADDRESS:
|
| |
PHONE NUMBER:
|
| ||||||
| |
**Beneficiary Name(s) that appears on the account at your financial institution — this MUST be the same name and address that your shares are
registered to |
| |||||||||
| | |
|
| | | | | | | | | | | | | | | | |
| | | | | |
**Beneficiary Address (Note: PO Boxes will not be accepted)
**City |
| | | **Province/State | | | | | | | |
**Postal Code/Zip Code
|
| | | | | |||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| |
**Beneficiary
Bank/Financial Institution |
| | | | | | | | | | |||||||||
| | |
|
| | | | | | | | | | | | | | | | |
| | | | | | **Bank Address **City | | | | **Province/State | | | | | | | |
**Postal Code/Zip Code
|
| | | | | |||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| |
PLEASE ONLY COMPLETE THE APPLICABLE BOXES BELOW, AS PROVIDED BY YOUR FINANCIAL INSTITUTION. YOU ARE NOT REQUIRED TO COMPLETE ALL BOXES
|
| |||||||||||||||
| | | | | | **Bank Account No. | | | |
Bank No. & Transit No. (Canadian
Banks) |
| | | | | | |
ABA/Routing No. (US
Banks) |
| | | | | |||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | (3 digits & 5 digits) (9 digits) | | | | | | | | | | | |||||||||
| | | | | |
SWIFT or BIC Code
|
| | |
IBAN Number
|
| | | | | | |
Sort Code (GBP)
|
| | | | | |||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | |
(11 characters — if you only have eight, put ‘XXX’ for the last three)
|
| ||||||||||||
| | | | |
Additional Notes and special routing instructions:
|
| ||||||||||||
| |
The Depositary for the Offer is:
|
|
| |
TSX Trust Company
|
|
| |
100 Adelaide Street West, Suite 301
Toronto, Ontario, M5H 4H1
Telephone: (416) 682-3860
Toll Free: 1-800-387-0825
Email: tsxt-corpact@tmx.com
Registered Mail, Hand or Courier
TSX Trust Company 301-100 Adelaide Street West Toronto, Ontario M5H 4H1 Attention: Corporate Actions |
|
| |
Tenders via Email: (only available to DRS/book-entry
shareholders) |
|
| |
tsxt-corpact@tmx.com
|
|
| | Tenders via In-Person, Courier, Registered Mail: | |
| |
301-100 Adelaide Street West
Toronto, Ontario M5H 4H1 Attention: Corporate Actions |
|
| | Inquiries | |
| |
North American Toll Free: 1-800-387-0825
Telephone: 1-416-682-3860 |
|
Common Shares of Arbutus Biopharma Corporation
Pursuant to the Offer (as defined herein)
Dated August 24, 2026
| | |
THE OFFER WILL EXPIRE AT 5:00 PM (NEW YORK CITY TIME) ON SEPTEMBER 29, 2026, OR AT SUCH LATER TIME AND DATE TO WHICH THE OFFER MAY BE EXTENDED BY THE COMPANY, UNLESS WITHDRAWN
(THE “EXPIRATION DATE”) |
| |
OR REGISTERED MAIL
100 Adelaide Street West
Suite 301
Toronto, Ontario
M5H 4H1
Attention: Corporate Actions
tsxt-corpact@tmx.com
| | |
NAME(S) OF REGISTERED OWNER(S)
(Please Fill in Exactly as Name(s) Appear(s) on Share Certificate(s)) |
| |
| | | | |
| | |
Share Certificate Number(s) — If Available
|
| | |
Number of Shares
Represented by Certificate(s) |
| | |
Number of Shares
Deposited |
| |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | |
BOX A
TYPE OF TENDER |
| |
| | |
CHECK ONLY ONE BOX; IF MORE THAN ONE BOX IS CHECKED, OR IF NO BOX IS CHECKED, THE TENDER WILL BE DEEMED TO BE A PURCHASE PRICE TENDER
|
| |
| | |
SHARES ARE BEING TENDERED HEREBY PURSUANT TO:
|
| |
| | | ☐ An Auction Tender ☐ A Purchase Price Tender ☐ A Proportionate Tender | | |
| | | (Complete Box C) | | |
| | | | | |
| | |
BOX B
ODD LOTS* |
| |
| | | To be completed ONLY if Shares are being tendered by or on behalf of persons owning fewer than 100 Shares as of the close of business on the Expiration Date. | | |
| | | The undersigned either (check one): | | |
| | | ☐ is the owner of fewer than 100 Shares as of the close of business on the Expiration Date, all of which are tendered; or | | |
| | | ☐ is a broker, dealer, commercial bank, trust company or other nominee that (i) is tendering, for the beneficial owners thereof, Shares with respect to which it is the record owner, and (ii) believes, based upon representations made to it by each such beneficial owner, that such beneficial owner owns an aggregate of fewer than 100 Shares as of the close of business on the Expiration Date and is tendering all such Shares. | | |
| | | *Odd Lot Holders may not tender their Shares pursuant to a Proportionate Tender. | | |
| | |
BOX C
AUCTION TENDERS |
| |
| | | Price (in US$) per Share: | | |
| | | In addition to checking “Auction Tender” in Box A above, this box MUST be completed if Shares are tendered pursuant to an Auction Tender. | | |
| | |
Check Only ONE Box. If more than one box is checked, or if no box is checked, all Shares identified above will be deemed to have been tendered pursuant to the Purchase Price Tender. Shareholders (other than Odd Lot Holders) may make multiple Auction Tenders but not in respect of the same Shares. If a Shareholder wishes to tender different Shares at different prices, a separate tender instruction by way of Letter of Transmittal must be submitted for EACH such tender.
|
| |
| | |
☐ $5.00
|
| |
☐ $5.05
|
| |
☐ $5.10
|
| |
☐ $5.15
|
| |
☐ $5.20
|
| |
☐ $5.25
|
| |
☐ $5.30
|
| |
☐ $5.35
|
| |
| | |
☐ $5.40
|
| |
☐ $5.45
|
| |
☐ $5.50
|
| |
☐ $5.55
|
| |
☐ $5.60
|
| |
☐ $5.65
|
| |
☐ $5.70
|
| |
☐ $5.75
|
| |
| | |
BOX D
CURRENCY ELECTION |
| |
| | | All cash payments will be made in U.S. dollars, unless Shareholders elect to use the Depositary’s currency exchange services to convert their payment into, and have such payment made, in Canadian dollars by checking the box below. If you do not check the box below, your payment will be issued in United States dollars. | | |
| | | ☐ Check here if you wish to have your cash entitlement paid in Canadian dollars (C$) | | |
| | | Notice: By checking the box above, you acknowledge and agree that (a) the exchange rate for one U.S. dollar expressed in Canadian dollars will be the rate available from TSX Trust Company, in its capacity as foreign exchange service provider, on the date on which the funds are converted, which rate will be based on the prevailing market rate on such date, and (b) the risk of any fluctuations in such rate, including risks relating to the particular date and time at which funds are converted, will be solely borne by the Shareholder. TSX Trust Company will act as principal in such currency conversion transactions. | | |
| | | Dated: | | | |
Telephone (Business
Hours): ( ) |
| | | Signature: | | |
| | | Email: | | | | Address: | | | | | | |
(Not to be used for signature guarantees)
| |
NAME OF FIRM
|
| |
AUTHORIZED SIGNATURE
|
|
| |
|
| |
|
|
| |
|
| |
NAME
|
|
| |
ADDRESS OF FIRM
|
| | | |
| |
|
| |
TITLE
|
|
| |
TELEPHONE NUMBER
|
| |
|
|
| |
|
| |
DATED
|
|
by
of
Up to US$230 Million in Value of Its Common Shares
At a Cash Purchase Price Not Greater than US$5.75 per Share
Nor Less than US$5.00 per Share
| | |
THE OFFER WILL EXPIRE AT 5:00 P.M. (NEW YORK CITY TIME)
ON SEPTEMBER 29, 2026, OR AT SUCH LATER TIME AND DATE TO WHICH THE OFFER MAY BE EXTENDED BY THE COMPANY, UNLESS WITHDRAWN (THE “EXPIRATION DATE”) |
| |
270 Park Avenue
New York, New York 10017
Call Toll Free: 1 (877) 371-5947
Suite 4500, TD Bank Tower
66 Wellington Street West
Toronto, Ontario
Canada M5K 1E7
by
of
Up to US$230 Million in Value of Its Common Shares
At a Cash Purchase Price Not Greater than US$5.75 per Share
Nor Less than US$5.00 per Share
| | | THE OFFER WILL EXPIRE AT 5:00 P.M. (NEW YORK CITY TIME) ON SEPTEMBER 29, 2026, OR AT SUCH LATER TIME AND DATE TO WHICH THE OFFER MAY BE EXTENDED BY THE COMPANY, UNLESS WITHDRAWN (THE “EXPIRATION DATE”) | | |
| | |
BOX A
TYPE OF TENDER
CHECK ONLY ONE BOX, IF MORE THAN ONE BOX IS CHECKED, OR IF NO BOX IS CHECKED, THE TENDER WILL BE DEEMED TO BE A PURCHASE PRICE TENDER.
SHARES ARE BEING TENDERED HEREBY PURSUANT TO:
|
| | ||||||
| | | ☐ An Auction Tender | | | ☐ A Purchase Price Tender | | | ☐ A Proportionate Tender | | |
| | |
(Complete Box B)
|
| | | | |
(Complete Box C)
|
| |
| | |
BOX B
AUCTION TENDERS |
| | ||||||||||||||||||||||||||||
| | | In addition to checking “Auction Tender” in Box A above, this Box MUST be completed if Shares are being tendered pursuant to an Auction Tender. | | | ||||||||||||||||||||||||||||
| | | Check only ONE box to indicate the Auction Tender price. If more than one box is checked, or if no box is checked, all Shares identified above will be deemed to have been tendered pursuant to the Purchase Price Tender. Shareholders (other than Odd Lot Holders) may make multiple Auction Tenders but not in respect of the same Shares. If a Shareholder wishes to tender different Shares at different prices, a separate tender instruction must be submitted for EACH such tender. | | | ||||||||||||||||||||||||||||
| | | Price (in US$) per Share. | | | ||||||||||||||||||||||||||||
| | | ☐ $5.00 | | | | ☐ $5.05 | | | | ☐ $5.10 | | | | ☐ $5.15 | | | | ☐ $5.20 | | | | ☐ $5.25 | | | | ☐ $5.30 | | | | ☐ $5.35 | | |
| | | ☐ $5.40 | | | | ☐ $5.45 | | | | ☐ $5.50 | | | | ☐ $5.55 | | | | ☐ $5.60 | | | | ☐ $5.65 | | | | ☐ $5.70 | | | | ☐ $5.75 | | |
| | |
BOX C
PROPORTIONATE TENDER |
| | ||||
| | |
In addition to checking “Proportionate Tender” in Box A above, this Box C MUST be completed if Shares are being tendered pursuant to a Proportionate Tender.
A Shareholder who makes a Proportionate Tender will be deemed to have agreed to sell to the Company at the Purchase Price a number of Shares that will result in the Shareholder maintaining its proportionate equity ownership in the Company following completion of the Offer. Registered Shareholders may make a Proportionate Tender and non-registered Shareholders may instruct their nominees to make a Proportionate Tender. All Shareholders who make a Proportionate Tender must indicate the total number of Shares they own below. A registered Shareholder who makes a Proportionate Tender must deposit either all of its Shares or a sufficient number of Shares to satisfy the Shareholder’s Proportionate Tender. This number of Shares can be calculated by multiplying the total number of Shares owned by the Shareholder by 0.2322 (rounded down to the nearest whole number of Shares). A non-registered Shareholder who wishes its nominee to make a Proportionate Tender must deposit all of its Shares.
If a non-registered Shareholder wishes to become a registered Shareholder in order to make a Proportionate Tender by depositing only a sufficient number of Shares, the Shareholder should immediately contact its investment dealer, stock broker, bank, trust company or other nominee in order to take the necessary steps to have its Shares registered in the Shareholder’s name prior to tendering Shares pursuant to the Offer. A Shareholder who makes an invalid Proportionate Tender, including by tendering an insufficient number of Shares, will be deemed to have made a Purchase Price Tender.
|
| | ||||
| | | | | | | | | |
| | | Total number of Shares owned by the Shareholder: | | | | | | |
| | |
BOX D
CURRENCY ELECTION |
| |
| | | All cash payments will be made in U.S. dollars, unless Shareholders elect to use the Depositary’s currency exchange services to convert their payment into, and have such payment made, in Canadian dollars by checking the box below. If you do not check the box below, your payment will be issued in United States dollars. | | |
| | | ☐ Check here if you wish to have your cash entitlement paid in Canadian dollars (C$) | | |
| | | Notice: By checking the box above, you acknowledge and agree that (a) the exchange rate for one U.S. dollar expressed in Canadian dollars will be the rate available from TSX Trust Company, in its capacity as foreign exchange service provider, on the date on which the funds are converted, which rate will be based on the prevailing market rate on such date, and (b) the risk of any fluctuations in such rate, including risks relating to the particular date and time at which funds are converted, will be solely borne by the Shareholder. TSX Trust Company will act as principal in such currency conversion transactions. | | |
Biopharma Corporation’s
Tender Offer to Purchase for Cash up to US$230 Million of Its Common Shares
Tuan
Tender Offer of its Common Shares at a Price
Not Greater Than US$5.75
Nor Less Than US$5.00 Per Share
Exhibit 99.1
FORM 51-102F3
Material Change Report
Item 1 Name and Address of Issuer
Arbutus Biopharma Corporation (“Arbutus” or the “Company”)
701 Veterans Circle
Warminster, Pennsylvania USA
18974
Item 2 Date of Material Change
August 24, 2026
Item 3 News Release
A news release announcing the material change was issued by the Company on August 24, 2026, which was disseminated through the facilities of Globe Newswire and subsequently filed with the SEC at www.sec.gov and SEDAR+ at www.sedarplus.com.
Item 4 Summary of Material Change
On August 24, 2026, Arbutus announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation (the “Offer”) up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than US$5.75 per Share. The Offer will proceed by way of a modified Dutch auction that includes the ability for shareholders to participate via a proportionate tender. Arbutus has obtained exemptive relief from the applicable Canadian securities regulatory authorities with respect to the proportionate take-up and extension requirements of the Offer. Arbutus has also obtained exemptive relief from the SEC to permit shareholders to participate via proportionate tender.
The Offer begins today, August 24, 2026, and will expire at 5:00 p.m., New York City time, on September 29, 2026, unless withdrawn, extended or varied by the Company.
Item 5 Full Description of Material Change:
5.1 Full Description of Material Change
On August 24, 2026, Arbutus announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its Shares at a price of not less than US$5.00 and not more than US$5.75 per Share. Arbutus has obtained exemptive relief from (i) applicable Canadian securities regulatory authorities with respect to the proportionate take-up and extension requirements of the Offer and (ii) the Securities and Exchange Commission to permit shareholders to participate via proportionate tender.
The Offer begins today, August 24, 2026 and will expire at 5:00 p.m. New York City time, on September 29, 2026, unless withdrawn, extended or varied by the Company.
The Offer will be for up to approximately 23.2% of the total number of issued and outstanding shares on a non-diluted basis (based on a purchase price equal to the minimum purchase price per share and 198,105,743 Shares issued and outstanding as at the close of business on August 19, 2026).
Shareholders wishing to tender to the Offer will be entitled to do so by making: (i) an auction tender for a specified price (the “Auction Price”) of not less than US$5.00 and not more than US$5.75 per Share in increments of US$0.05 per Share (the “Auction Tenders”), (ii) a purchase price tender without specifying a price per Share, but rather agreeing to have a specified number of Shares purchased at the Purchase Price (as defined below) (the “Purchase Price Tenders”), or (iii) a proportionate tender in which they will agree to sell, at the Purchase Price, that number of Shares that will result in them maintaining their respective proportionate Share ownership in the Company (the “Proportionate Tenders”), in each case on the terms and subject to the conditions described in the Offer to Purchase and Bid Circular, the Letter of Transmittal and other tender offer materials.
Certain of the Company’s directors and executive officers have indicated that they intend to tender up to an aggregate of 682,630 Shares in the Offer through Purchase Price Tenders. Roivant Sciences Ltd. (“Roivant”) is the beneficial owner of 38,847,462 Shares, which represents approximately 19.6% of all issued and outstanding Shares as of August 19, 2026. Roivant has advised the Company that it intends to make a Proportionate Tender.
The Company will determine a single price per Share (the "Purchase Price"), not less than US$5.00 and not more than US$5.75 per Share (in increments of US$0.05 per Share), that the Company will pay for Shares properly tendered to and not properly withdrawn from the Offer, taking into account the Auction Prices and the number of Shares deposited pursuant to Auction Tenders and Purchase Price Tenders. The Purchase Price will be the lowest price per Share which enables Arbutus to purchase all of the Shares tendered pursuant to valid Auction Tenders and Purchase Price Tenders, at the Purchase Price, after taking into account the number of Shares tendered pursuant to valid Proportionate Tenders, which aggregate amount shall not exceed an aggregate of US$230,000,000. Shares deposited at or below the finally determined Purchase Price will be purchased at such Purchase Price. Shares that are not taken up in connection with the Offer, including Shares deposited pursuant to Auction Tenders at prices above the Purchase Price, will be returned to Shareholders that tendered to the Offer.
If the aggregate purchase price for Share validly tendered and not withdrawn pursuant to Auction Tenders and Purchase Price Tenders would collectively result in an aggregate purchase price in excess of the amount available for Auction Tenders and Purchase Price Tenders, Arbutus will purchase Shares from the shareholders who made Purchase Price Tenders or tendered their Shares at or below the finally determined Purchase Price on a pro rata basis, except that “odd lot” holders (holders of less than 100 Shares) will not be subject to proration. Regardless of proration, the Company will always purchase at the Purchase Price such number of Shares from shareholders making valid Proportionate Tenders that results in such tendering shareholders maintaining their respective proportionate Share ownership in the Company following the completion of the Offer (subject to nominal differences due to the quantity of Shares purchased from such shareholders being rounded down to the nearest whole number of Shares to avoid the purchase of fractional Shares).
Arbutus expects to mail the formal offer to purchase and bid circular, letter of transmittal, notice of guaranteed delivery (collectively, the “Offer Documents”) containing the terms and conditions of the Offer, instructions for tendering Shares and the factors considered by Arbutus and its board of directors (the “Board of Directors”) in determining to approve the Offer, among other considerations, on or about August 24, 2026. The Offer Documents will be filed with the applicable securities regulators in Canada and the United States and will be available free of charge on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Shareholders should read the Offer Documents prior to making a decision with respect to the Offer.
The Board of Directors has approved the making of the Offer and the price range for the purchase of Shares. However, none of Arbutus, the Board of Directors, the dealer manager, the information agent or the depositary makes any recommendation to any shareholder as to whether to deposit or refrain from depositing Shares under the Offer. Shareholders are urged to evaluate carefully all information in the Offer, consult their own financial, legal, investment and tax advisors and make their own decisions whether to deposit Shares under the Offer, how many Shares to deposit, whether to deposit Shares pursuant to the same tender option or different tender options and whether to specify a price or prices and, if so, at what price or prices to deposit such Shares.
This material change report does not constitute an offer to buy or the solicitation of an offer to sell Shares. The Offer will be optional for all shareholders, who will be free to choose whether to participate, how many Shares to tender and, in the case of Auction Tenders, at what price to tender within the specified range. Any shareholder who does not deposit any Shares (or whose Shares are not repurchased under the Offer) will realize a proportionate increase in equity interest in Arbutus, to the extent that Shares are purchased under the Offer.
Arbutus has retained J.P. Morgan Securities LLC to act as dealer manager. The Company has also engaged TSX Trust Company to act as depositary and Georgeson, LLC to act as information agent.
5.2 Disclosure for Restructuring Transactions
Not applicable.
Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102
Not applicable.
Item 7 Omitted Information
No significant facts otherwise required to be disclosed in this report have been omitted.
Item 8 Executive Officer
The following executive officer of the Company is knowledgeable about the material change and may be contacted respecting the change:
Tuan Nguyen, Chief Financial Officer
701 Veterans Circle
Warminster, Pennsylvania
USA 18974
Telephone: (267) 469-0914
Item 9 Date of Report
August 24, 2026
Forward-Looking Statements and Information
This material change report contains forward-looking statements, and forward-looking information within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this material change report include, but are not limited to: statements about the Offer, including the expected expiration, timing and completion of the Offer; the amount and pricing of the Offer; availability of funding for the Offer; participation in the Offer or tender intentions of certain directors, executive officers and Roivant, the mailing of the Offer Documents to shareholders, and other terms and conditions of the Offer, all of which involve known and unknown risks, uncertainties and other factors that may cause actual results and other events to be materially different from those expressed or implied in such forward-looking statements.
The forward-looking statements contained in this material change report are subject to a number of material factors that could cause actual results to differ materially, including the impact of share price volatility on the Offer; the risk that the Offer will not be completed on the terms described in this material change report (including the price range and number of Shares that Arbutus may purchase pursuant to the Offer), or at all; the risk that the conditions of the Offer are not satisfied or waived; developments or changes in general economic or market conditions, developments or changes in the securities markets; and developments or changes in the Company’s business, financial condition or cash flows.
A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K for the most recent fiscal year as filed with the SEC, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sec.gov and at www.sedarplus.ca. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus undertakes no obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.